Liraglutide
Liraglutide (Victoza, Saxenda) is a heavily engineered, daily-administered GLP-1 receptor agonist that fundamentally altered the landscape of modern endocrinology and obesity medicine. By heavily augmenting the body's natural incretin system, it exerts brutal, unyielding control over severe hyperphagia (binge eating) while profoundly sensitizing the organism to insulin. Favored over its weekly counterparts exclusively in scenarios requiring rapid dosage titration or surgical precision in drug clearance, it acts as a highly reliable, pharmacological wrecking ball against severe metabolic syndrome and profound insulin resistance.
Quick Stats
Scientific Data
Mechanism of Action
Liraglutide is a GLP-1 receptor agonist with 97% sequence homology to native human GLP-1. A C18 fatty acid chain attached to Lys26 enables reversible albumin binding, extending the half-life from ~2 minutes (native GLP-1) to approximately 13 hours — enabling once-daily dosing.
Liraglutide activates GLP-1R on pancreatic beta cells (glucose-dependent insulin secretion), hypothalamic satiety neurons (reduced appetite), gastric pacemaker cells (delayed gastric emptying), and cardiac tissue (cardioprotective). It is FDA-approved at 1.8 mg for T2DM (Victoza) and at 3 mg for obesity (Saxenda). As the first-generation daily GLP-1 RA, liraglutide established the clinical framework later succeeded by weekly semaglutide.
Source: FDA Label (Saxenda), PMID: 24665709 (SCALE trial)
Background & History
Liraglutide was developed by Novo Nordisk and approved by the FDA in 2010 as Victoza for type 2 diabetes and in 2014 as Saxenda (3 mg/day) for obesity — making it the first GLP-1 agonist approved specifically for weight management. It has 97% sequence homology to human GLP-1 and a C18 fatty acid chain that enables albumin binding, extending the half-life from 2 minutes (native GLP-1) to 13 hours. Clinical trials (SCALE, 2015) demonstrated 8% body weight loss at the 3 mg dose. While now partially succeeded by semaglutide in the market, liraglutide remains widely prescribed globally due to its long safety record (13+ years), mature generics pipeline, and once-daily dosing flexibility.
Research Use Cases
- ✓Type 2 diabetes management (Victoza, 1.2-1.8 mg/day)
- ✓Chronic weight management (Saxenda, 3 mg/day)
- ✓Cardiovascular risk reduction in T2D (LEADER trial: 13% CV mortality reduction)
- ✓NASH (non-alcoholic steatohepatitis) — signal in Phase II trials
- ✓Bridging therapy before higher-potency GLP-1 agents
Dosing Protocol
| Typical Dose | 0.6-3 mg/day |
| Frequency | 1× daily |
| Half-Life | ~13 hours |
| Common Vial Sizes | 6 mg, 18 mg |
Dosing Protocols
Titration (Weeks 1-4)
T2DM Maintenance (Victoza)
Obesity (Saxenda)
Administration
Expected Timeline
Who Is It For?
Type 2 Diabetes
HighFDA-approved. LEADER trial showed 22% reduction in cardiovascular mortality. HbA1c reduction of ~1-1.5%.
Obesity / Weight Loss
HighFDA-approved (Saxenda). 5-8% body weight reduction at 56 weeks. Now largely superseded by semaglutide.
Reconstitution Example
Safety & Considerations
FDA-approved (Victoza, Saxenda). Common: nausea, vomiting, diarrhea (improve with slow titration). Black box warning: thyroid C-cell tumors in rodents (human relevance unclear). Contraindicated in personal/family history of MTC or MEN2. Monitor for pancreatitis.
Regulatory & Legal Status
FDA-approved as Victoza® (T2D) and Saxenda® (obesity)
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Prescription Drug
US Compounding: Available via licensed pharmacy Rx
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Same MTC/MEN2 contraindications as all GLP-1 agonists. Daily injections vs weekly for semaglutide — important adherence consideration. GI side effects (nausea, diarrhea) are more sustained than semaglutide due to shorter half-life creating less smooth exposure. Adjust timing of oral medications (slowed gastric emptying affects absorption). Pancreatitis risk — discontinue if persistent abdominal pain.
Synergies & Common Stacks
BPC-157's GI-protective effects may help manage liraglutide-induced nausea and gastric side effects during dose escalation, improving tolerability.
Liraglutide drives appetite suppression and metabolic improvement; AOD-9604 adds targeted lipolysis. Complementary fat loss approaches without GLP-1 receptor overlap.
Liraglutide vs. Semaglutide
| Attribute | Liraglutide | Semaglutide |
|---|---|---|
| Dosing | Daily injection (1.2–1.8 mg/day) | Once weekly injection (0.5–2.4 mg/wk) |
| Peak Weight Loss | ~8% (SCALE trials) | 14.9–17% (STEP trials) |
| Mechanism | GLP-1 agonist | GLP-1 agonist (same class, newer generation) |
| Cardiovascular | Proven (LEADER trial) | Proven (SUSTAIN-6) |
| Convenience | Daily — less convenient | Weekly — more convenient |
Verdict: Semaglutide is the modern upgrade to liraglutide: dramatically better weight loss efficacy (~2× improvement) and once-weekly dosing vs. daily. Most clinicians prefer semaglutide unless specific insurance or tolerance considerations apply.
Dosing Quick Reference
Frequently Asked Questions
Is liraglutide better than semaglutide for weight loss?▼
How is liraglutide injected?▼
References
- Marso SP et al. “"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)".” NEJM (2016). PMID: 27295427
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code